肌层浸润性膀胱癌的围手术期免疫治疗。
Perioperative Immunotherapy in Muscle-invasive Bladder Cancer.
机构信息
Department of Medicine, Section of Hematology Oncology, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA.
Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA.
出版信息
Eur Urol Oncol. 2021 Apr;4(2):131-133. doi: 10.1016/j.euo.2021.01.004. Epub 2021 Feb 26.
Immune checkpoint inhibitors (ICIs) have already been approved for the treatment of metastatic urothelial carcinoma and are now being investigated for perioperative treatment of muscle-invasive bladder cancer (MIBC). Ongoing trials are assessing ICIs as monotherapy and in combination with other treatments. Early data are promising, and long-term survival data are awaited to confirm the potential of ICIs in MIBC.
免疫检查点抑制剂（ICIs）已被批准用于治疗转移性尿路上皮癌，目前正在研究其用于肌层浸润性膀胱癌（MIBC）的围手术期治疗。正在进行的试验评估了 ICI 作为单药治疗以及与其他治疗联合应用的效果。早期数据令人鼓舞，需要等待长期生存数据来确认 ICI 在 MIBC 中的潜力。
Zotero 插件